Article

Immunosignaturing Microarrays Distinguish Antibody Profiles of Related Pancreatic Diseases

2013-01-01

Abstract excerpt

Immunosignaturing is a technology that allows the humoral immune response to be observed through the binding of antibodies to random sequence peptides. Profiles of the antibody repertoire produced during infection or during long-term chronic disease have proven to be informative for disease classification. An important unanswered question relative to this technology is whether different diseases that target the sa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a8d6a5bf-cfa5-5248-89c7-02747f316115
DOI: 10.4172/jpb.s6-001

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunosignaturing Microarrays Distinguish Antibody Profiles of Related Pancreatic DiseasesDOI 10.4172/jpb.s6-001Read

Immunosignature system for diagnosis of cancerSemantic proximity Read

Glycans Related to the CA19-9 Antigen Are Increased in Distinct Subsets of Pancreatic Cancers and Improve Diagnostic Accuracy Over CA19-9Semantic proximity Read

Seromic profiling of ovarian and pancreatic cancerSemantic proximity Read

Dual-color Proteomic Profiling of Complex Samples with a Microarray of 810 Cancer-related AntibodiesSemantic proximity Read

Novel Autoimmune Hepatitis-Specific Autoantigens Identified Using Protein Microarray TechnologySemantic proximity Read

IgG N-glycan Signatures as Potential Diagnostic and Prognostic BiomarkersSemantic proximity Read

Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseasesSemantic proximity Read

Comparative quantitative proteomic analysis of disease stratified laser captured microdissected human islets identifies proteins and pathways potentially related to type 1 diabetesSemantic proximity Read

Detection of pancreatic cancer using antibody microarray‐based serum protein profilingSemantic proximity Read

Plasma protein biomarkers predict the development of persistent autoantibodies and type 1 diabetes 6 months prior to the onset of autoimmunitySemantic proximity Read

Physical Characterization of the “Immunosignaturing Effect”Semantic proximity Read

Protein and Peptide Array Analysis of Autoimmune DiseaseSemantic proximity Read